Literature DB >> 9738846

Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.

M H Nguyen1, C Y Yu.   

Abstract

We compared the in-vitro activity of fluconazole, itraconazole, ketoconazole and voriconazole against 67 blood isolates of Candida spp. exhibiting a wide range of fluconazole MICs (0.125 to >64 mg/L). Voriconazole was the most potent in vitro, followed by itraconazole, ketoconazole and fluconazole. Itraconazole and voriconazole had in-vitro activity against fluconazole-susceptible and -resistant candida isolates. Higher itraconazole and voriconazole MICs were observed in isolates exhibiting higher fluconazole MICs, suggesting cross-resistance. Itraconazole and voriconazole MICs of > or =16 mg/L were observed only in Candida albicans and Candida tropicalis. Candida krusei and Candida glabrata exhibited itraconazole MICs of 0.5-1 mg/L and voriconazole MICs of 0.25-0.5 mg/L.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9738846     DOI： 10.1093/jac/42.2.253

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  9 in total

1.  Molecular analysis and susceptibility profiling of Candida albicans isolates from immunocompromised patients in South India.

Authors:  C P Girish Kumar; Ahmed Medhat Hanafy; Masakazu Katsu; Yuzuru Mikami; Thangam Menon
Journal:  Mycopathologia       Date:  2006-03       Impact factor: 2.574

2.  Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors:  S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.

Authors:  M Lozano-Chiu; S Arikan; V L Paetznick; E J Anaissie; J H Rex
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

4.  Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital.

Authors:  Krishnapriya Kalaiarasan; Rakesh Singh; Latha Chaturvedula
Journal:  J Clin Diagn Res       Date:  2017-03-01

5.  Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

Authors:  Paul A Mann; Raulo M Parmegiani; Shui-Qing Wei; Cara A Mendrick; Xin Li; David Loebenberg; Beth DiDomenico; Roberta S Hare; Scott S Walker; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

6.  Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei.

Authors:  Takashi Fukuoka; Douglas A Johnston; Carol A Winslow; Marcel J de Groot; Catherine Burt; Christopher A Hitchcock; Scott G Filler
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 7.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Authors:  A Espinel-Ingroff; K Boyle; D J Sheehan
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

Review 8.  Conazoles.

Authors:  Jan Heeres; Lieven Meerpoel; Paul Lewi
Journal:  Molecules       Date:  2010-06-09       Impact factor: 4.411

9.  In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey.

Authors:  Gulgun Yenisehirli; Nermin Bulut; Aydan Yenisehirli; Yunus Bulut
Journal:  Jundishapur J Microbiol       Date:  2015-09-08       Impact factor: 0.747
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.